Behind The Markets DNA Hacking Review 2025: Dylan Jovine’s CRISPR Stock Pick Exposed

In this Behind The Markets “DNA Hacking” review, I’ll walk you through Dylan Jovine’s take on a breakthrough built on CRISPR technology.

Table of Contents show

He believes this discovery could reshape how we treat thousands of genetic diseases and create rare profit opportunities along the way.

The idea sounds bold, but Jovine has a history of spotting big trends before the crowd, which makes this worth a closer look.

>> Join Behind The Markets Now <<

What is Behind The Markets?

Behind The Markets is Dylan Jovine’s flagship research service designed to give readers a front-row seat to the same kinds of opportunities he shares with close contacts. It taps into Jovine’s decades of Wall Street experience, his connections with scientists and industry insiders, and his ability to spot disruptive trends before they go mainstream.

Every month, subscribers get a fresh issue featuring one carefully researched stock idea, along with Jovine’s reasoning and clear instructions on when to buy and when to exit.

The service isn’t limited to one sector, though Jovine has a strong passion for biotech. He also digs into technology, energy, and undervalued small caps whenever the numbers make sense.

Members can follow along with a model portfolio, receive timely updates when news breaks, and access everything through a secure online hub.

I’ll perform a deep dive shortly, but first I want to understand a bit more about the guru behind it all.

>> Like Behind the Markets investment strategy? Sign up now! <<

Who is Dylan Jovine?

Dylan Jovine started his Wall Street journey back in 1991 when investment banker Peter Jaquith saw raw potential in him.By his twenties, he was among the youngest market makers out there, trading alongside Goldman Sachs veterans and learning the business at the highest levels.

He later founded and ran Lexington Capital Partners, where he focused on both private and public investments.

After selling his stake in the company for a substantial sum, Jovine launched Tycoon Publishing in 2004 to be a conduit for his research.

After a personal health battle in 2013 introduced him to the potential of gene therapy, he shifted part of his focus toward biotech investing, eventually launching Behind The Markets in 2018 to share his research with individual readers.

Is Dylan Jovine Legit?

Jovine has built credibility through a mix of accurate market calls and consistent publishing.

He gained recognition for predicting the 2008 housing crash a year in advance, and more recently he called the sharp Covid rebound and the persistence of inflation when many experts disagreed.
He has also been invited to Washington, D.C. to meet with President George W. Bush and Vice President Dick Cheney, and his work has been cited in mainstream financial media.

Since 2018, his advisory has reported a 75.2% win rate on closed trades and an average return of 43.8% across all picks, results that compare favorably with most advisory services.

With more than thirty years of experience, published books, and a documented track record of big calls, Jovine has established himself as a legitimate voice in the investment research space.

>> Get Dylan’s latest insights and research reports today! <<

What is the “DNA Hacking” Presentation?

When Dylan Jovine talks about “DNA Hacking,” he’s pointing to a discovery that has the potential to change the way we think about illness altogether. Instead of designing one expensive drug at a time to treat one condition, what’s known as CRISPR technology makes it possible to edit defective DNA directly. That means the same approach could be used to tackle thousands of genetic diseases.

For anyone following this story, the promise isn’t just medical, it’s financial. A breakthrough like this has the power to create enormous opportunities for early movers.

Why Timing Is Critical

The current system of drug development is slow, costly, and leaves most genetic conditions untreated. On the other hand, CRISPR is already attracting billions from companies like Pfizer, Eli Lilly, Bayer, and Johnson & Johnson.

Bill Gates and Google Ventures have also committed major funding. It has already been used to cure patients suffering from sickle-cell disease and other rare conditions.

Hearing that level of validation from both the scientific community and Wall Street makes you realize this isn’t theory anymore; it’s happening right now. That’s why Jovine believes the timing to look deeper into this space is critical.

Three Ingredients to Success

Biotech can be a scary field, and actual breakthrough stocks seem infinitely less likely than duds.

Luckily, Dylan found three crucial ingredients that he believes need to exist for a biotech company to grow.

First, it must already have a patent in place. Not only are you investing in reality, but the company also benefits from anyone using it.

For a startup, Jovine states that it must have a strategic partner that knows the ins and outs of a particular product.

Finally, said biotech needs to have the ability to survive a credible patent challenge.

While it may not be a cut-and-dry investment strategy, it’s incredibly helpful for weeding out hundreds if not thousands of firms destined to fall by the wayside.

With this helpful tool in our pockets, let’s see how Jovine ties everything together.

>> Sign up now to access Dylan’s top picks <<

How to Profit from “DNA Hacking”

The presentation highlights a small company at the center of this revolution, one that holds a critical patent and has already proven its technology by partnering with big pharmaceutical firms.
According to Jovine, this company is positioned either for a massive independent run or to be acquired at a premium.

The key point is that the chance to buy in before the mainstream catches on won’t last forever.

You can get instant access to this promising play, but only if you sign up for Dylan’s Behind the Markets service.

It’s an opportunity that could reshape portfolios just as much as it reshapes medicine, and in the next section, I’ll show you exactly what’s included when you sign up.

DNA Hacking Review: What Comes With Behind The Markets?

Here’s a closer look at what a Behind the Markets membership includes:

One Year of Behind the Markets Investment Advisory Service

A full year of membership gives you steady access to Dylan Jovine’s research and recommendations.

Each monthly issue dives deep into one carefully selected stock, backed by data, insider contacts, and his decades of Wall Street experience.

Jovine doesn’t just tell you what ticker to buy; he explains the reasoning, the catalysts that could drive growth, and when to consider exiting the position.

These aren’t rushed ideas; they’re meant to be actionable strategies you can follow with confidence in a format that’s easy to follow along with.

It’s worth noting that Dylan doesn’t solely focus on biotech, giving a range of recommendations you can take advantage of.

Access to Model Portfolio

Dylan tracks every open recommendation here in his model portfolio alongside the buy prices, sell targets, and performance history.

Instead of leaving readers to guess what to do next, the portfolio makes it clear which stocks are still active and which ones have already hit their targets.

Jovine generally adds around one new stock each month, but the portfolio also shows how earlier ideas are progressing, so you can decide where to focus your money.

Having this transparency helps you follow along with discipline rather than emotion.

If you’ve ever struggled with knowing when to hold on and when to sell, this feature provides the structure and clarity needed to stick with a plan and avoid second-guessing every move.

>> Get Access to Model Portfolio NOW!<<

Regular Updates

The stock market doesn’t wait, and neither does Dylan Jovine.

Whenever a portfolio company announces earnings, faces an FDA decision, or becomes the subject of breaking news, members hear from him the same day.

These updates are direct, plain-language messages telling you what happened and what action, if any, you should take.

That immediacy is what sets the service apart, because you’re not left wondering how developments might affect your holdings.

Instead of second-guessing your moves, you can lean on Jovine’s experience and act with more confidence.

For readers who don’t have time to track headlines every hour, these real-time updates are one of the most practical parts of the membership.

24/7 Access to Website

Everything is organized inside a secure members-only website.

You can log in anytime to catch up on past issues, track the model portfolio, or revisit his bonus research.

This is especially useful if you join mid-year and want to catch up on earlier recommendations or revisit how certain ideas have played out over time.

The site is updated as soon as new guidance or commentary is released, so you’re always working with the latest information.

For busy readers balancing work and family, the flexibility of on-demand access means you can stay engaged on your own terms without worrying about missing a key update.

Behind The Markets Bonus Reports

Subscribers also receive a collection of in-depth research reports that expand on Jovine’s core recommendations:

Bonus Report #1: “Living Software” – The Small Company Revolutionizing Medicine

This report introduces readers to a biotech firm Jovine believes is at the center of the CRISPR revolution. He explains why its patent portfolio, partnerships with major pharmaceutical companies, and early clinical progress could position it as a leader in gene editing.

The report walks you through the science in simple terms while focusing on the business case, why this company has potential for explosive growth, and what catalysts could push it higher.

For anyone interested in getting exposure to the most talked-about area in biotech, this report is the starting point.

Bonus Report #2: Bullet-Proof: How to Create the Ideal Small Cap Biotech Stock Portfolio

Here, Jovine lays out a practical blueprint for spreading risk while maximizing upside in biotech investing. Small caps can be volatile, but by using his framework, readers learn how to choose the right mix of companies at different stages of development.

He discusses balancing clinical trial risk with pipeline diversity and shares methods for evaluating whether a stock is overhyped or underappreciated.

The goal is to help readers build a portfolio that can weather setbacks from one company while still leaving room for the big wins that drive biotech returns.

Bonus Report #3: Medical Money: How to Generate Monthly Income from Your Biotech Portfolio

This report explores how to transform biotech investing from a waiting game into a steady income source. Jovine explains how to identify biotech stocks that can provide dividends, royalties, or other cash flow opportunities while still offering growth potential.

He shows how pairing income-producing names with higher-risk plays gives readers both stability and upside.

It’s a practical guide for anyone who doesn’t want to simply buy and hope for years but instead prefers a strategy that can deliver ongoing rewards while waiting for breakthroughs to pay off.

Bonus Report #4: 3 Ingredients to Great Biotech Stocks

In this guide, Jovine shares the three characteristics he looks for before buying any biotech stock. He breaks down the importance of a strong management team, credible clinical data, and strategic partnerships.

Each element is explained with examples from real companies that either succeeded or failed based on these factors.

You’re given a filter you can use to quickly separate promising biotech plays from those with little chance of success.

It’s about giving readers a repeatable process to improve their decision-making and avoid costly mistakes.

Bonus Report #5: Tidal Wave: How the Medical Revolution Will Change Your Relationship with Your Doctor

This report shifts the focus to the broader transformation of healthcare. Jovine explains how biologics, gene therapies, and personalized medicine are replacing traditional chemical-based drugs. He outlines what this shift means for patients, doctors, and the companies driving innovation.

By looking at past revolutions in medicine and comparing them to what’s unfolding now, he shows how investors can anticipate where money will flow next.

Readers walk away with a clearer view of the future of healthcare and which areas are most likely to reward early investment.

Bonus Report #6: Pot Stocks: What the History of Cigarettes Can Teach Us About Investing in Cannabis

Jovine uses the history of the tobacco industry as a lens for understanding today’s cannabis market. He explains how regulation, consumer adoption, and consolidation shaped tobacco companies into dominant players, and how similar forces may play out in cannabis.

The report identifies the traits of cannabis companies that could follow the same path, giving readers a framework for evaluating this rapidly evolving sector.

Rather than speculating, readers learn how to use history as a guide for smarter decision-making in cannabis investing.

Bonus Report #7: 6 Questions to Ask Before Buying Any Stock

This final report serves as a practical checklist that can be applied beyond biotech.

Jovine outlines six key questions that force you to think about valuation, management, market size, competition, and catalysts.

By walking through these questions before buying, you avoid emotional decisions and ground your choices in a clear process.

He illustrates each question with past examples from his own research, showing how it helped him sidestep losses and capture big wins.

For readers, it’s a tool that adds discipline and consistency to their investing approach.

>> Join Now to Get these Bonus Reports <<

Refund Policy

Every membership comes with a 30-day, 100% money-back guarantee, which makes trying the service risk-free. If during the first month you feel the newsletter doesn’t meet your expectations, you can cancel for a full refund with no questions asked.

Importantly, you keep all the bonus reports you received, even if you decide not to continue.

This means you can explore the research, review Jovine’s stock recommendations, and still walk away with useful material at no cost if it’s not for you.

It’s a straightforward policy that shows confidence in the value of the service and gives readers peace of mind when signing up.

>> Sign up now under the 30-Day money-back guarantee <<

Pros and Cons

I’ve been through every inch of Jovine’s “DNA Hacking” bundle, and here are my top pros and cons:

Pros:

75.2% win rate since 2018
Access to CRISPR and biotech plays
Low-cost entry
Up-to-date model portfolio
Timely updates during volatility
7 Bonus Reports
30-day money-back guarantee

Cons:

Heavy biotech focus can be volatile
No community chat or forum

Behind The Markets Reviews by Members

The testimonials from Behind The Markets members provide useful insight into how the service performs in practice.
The general consensus is that Jovine’s work is well-grounded and trustworthy, which are essential for any service I invest in.

You’ll need to take these with a grain of salt since I pulled them off the Behind the Markets promo page, but it’s still proof that the service can deliver.

>> Sign up now to share these members’ amazing experiences <<

Behind The Markets Track Record/Past Performance

Since launching in 2018, Behind The Markets has built a performance record that Jovine frequently highlights as a key strength of the service.

The service has achieved a 75.2% win rate on closed trades, with an average return of 43.8% across all recommendations.

Some of the most notable wins include Palantir at +362%, C3.ai at +133%, and IONQ at +431%.

Beyond individual stock gains, Jovine has also earned credibility by calling major market events well in advance, including the 2008 housing crash, the Covid rebound in 2020, and the persistence of inflation in 2022.

His ability to combine big-picture forecasting with actionable stock picks gives members confidence that they’re not just chasing headlines but following a strategy with a proven track record.

While no performance is guaranteed, the results so far set a strong benchmark for what readers can expect from his research.

How Much Does Behind The Markets Cost?

The cost of joining Behind The Markets is designed to be accessible while still reflecting the depth of research Dylan Jovine provides.

The standard price is $199 per year, but the current DNA Hacking offer brings the cost down to just $49 for a full year.

This entry-level plan includes twelve monthly issues, access to the model portfolio, real-time updates, market commentary, and three bonus reports.

For readers who want more, there’s a $99 per year plan that unlocks all the bonus material I covered earlier in the review.

When you compare the potential payoff of a single winning stock to the subscription cost, the value becomes clear.

Even one solid trade idea could more than cover the price, which makes the discounted plans especially attractive for anyone interested in following Jovine’s research over the long term.

Is Behind The Markets Worth It?

When considering whether this service is worthwhile, it helps to weigh the price against what’s actually delivered. For less than $100 under the current promotion, members get a full year of stock recommendations, continuous updates, a live model portfolio, and access to seven comprehensive research reports.

That’s a substantial amount of guidance for a cost lower than most competing advisories. Even one successful trade could pay for the subscription many times over, which makes the value proposition clear.

Looking at performance, the win rate of over 75% and average returns above 40% provide reassurance that the ideas presented are not random speculation.

The service’s strength also lies in its focus on areas like biotech and CRISPR, which are risky but carry massive potential.

This balance of ambitious opportunities and disciplined research makes Behind The Markets appealing for readers who want more structure than going it alone.

From my perspective, as part of this Behind The Markets “DNA Hacking” review, the combination of affordability, track record, and refund protection makes it a strong choice for anyone seeking exposure to transformative market trends.